Skip to main content

Table 1 Characteristics of pancreatic ductal adenocarcinoma in patients with either resectable or nonresectable tumors

From: Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer

Characteristics

Resectable tumor (n= 230)

Non-resectable tumor (n= 458)

P value

Age (years)

62.1 ± 11.1

64.0 ± 12.0

0.047

  <65

136 (59.1%)

226 (49.3%)

0.015

  ≥65

94 (40.9%)

232 (50.7%)

 

Sex

  

0.749

  Male

143(62.2%)

279 (60.9%)

 

  Women

87 (37.8%)

179 (37.1%)

 

Symptoms

  

0.018

  Yes

225 (97.8%)

457 (99.8%)

 

  No

5 (2.2%)

1 (0.2%)

 

Physical findings

  

0.979

  Yes

166 (72.2%)

331 (72.3%)

 

  No

64 (27.8%)

127 (27.7%)

 

Bilirubin (mg/dl)

7.5 ± 9.1

7.2 ± 8.5

0.574

  ≤1.3

80 (36.5)

177 (42.3)

0.155

  >1.3

139 (63.5)

241 (57.7)

 

Albumin (g/dl)

3.77 ± 0.65

3.63 ± 0.71

0.025

  ≤3.5

61 (33.0%)

149 (43.3%)

0.020

  >3.5

124 (67.0%)

195 (56.7%)

 

AST (U/L)

112.9 ± 146.8

84.8 ± 99.2

0.011

  ≤68

110 (49.1%)

250 (60.1%)

0.008

  >68

114 (50.9%)

166 (39.9%)

 

CEA (ng/ml)

6.1 ± 8.1

13.5 ± 48.0

0.008

  ≤5

115 (67.6%)

180 (58.4%)

0.047

  >5

55 (32.4%)

128 (41.6%)

 

CA 19–9 (U/ml)

1,229.6 ± 4,680.4

1,616.4 ± 5,253.1

0.425

  ≤37

48 (27.1%)

46 (16.5%)

0.007

  >37

129 (72.9%)

232 (83.5%)

 

Operation time (minutes)

426.0 ± 155.3

219.2 ± 172.4

<0.0001

  ≤240

31 (13.9%)

285 (68.3%)

<0.0001

  >240

192 (86.1%)

132 (31.7%)

 

Complication

  

0.003

  Yes

55 (23.9%)

67 (14.6%)

 

  No

175 (76.1%)

391 (85.4%)

 

Death

  

0.017

  Yes

7 (3.0%)

36 (7.6%)

 

  No

223 (97.0%)

423 (92.4%)

 

Tumor size (cm)

4.6 ± 3.6

6.2 ± 3.5

<0.0001

  ≤3

94 (42.7%)

24 (15.8%)

<0.0001

  >3

126 (57.3%)

128 (84.2%)

 

Location

  

0.111

  Head of pancreas

165 (71.7%)

301 (65.7%)

 

  Not at head of pancreas

65 (28.3%)

157 (34.3%)

 

Differentiation

  

0.0002

  Well

83 (36.1%)

134 (29.3%)

 

  Moderate

105 (45.7%)

173 (37.8%)

 

  Poor

35 (15.2%)

103 (22.5%)

 

Others

7 (3.0%)

48 (10.5%)

 

Post-op C/T

  

<0.0001

  Yes

121 (52.6%)

163 (35.6%)

 

  No

109 (47.7%)

295 (64.4%)

 

Post-op R/T

  

0.255

  Yes

17 (7.4%)

46 (10.0%)

 

  No

213 (92.6%)

412 (90.0%)

 
  1. AST: aspartate aminotransferase; CEA: carcinoembryonic antigen; CA 19–9: carbohydrate antigen 19–9; Post-op C/T: postoperative chemotherapy; Post-op R/T: postoperative radiotherapy; Others: mixed tumor differentiation.
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us